EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Contribution of telacebec to novel drug regimens in a murine tuberculosis model

Oliver D Komm, Sandeep Tyagi, Andrew Garcia, Deepak Almeida, Yong Chang, Si-Yang Li, Jennie Ruelas Castillo, Paul J Converse, Todd Black, Nader Fotouhi, Eric L Nuermberger iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00962-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Oliver D Komm und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for TB Research, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis, Mice, Inbred BALB C, Diarylquinolines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical efficacy of combination drug regimens containing the first-generation diarylquinoline (DARQ) bedaquiline in the treatment of multidrug-resistant tuberculosis has validated ATP synthesis as a vulnerable pathway in Mycobacterium tuberculosis . New DARQs in clinical development may be even more effective than bedaquiline, including against emerging bedaquiline-resistant strains. Telacebec (T) is a novel cytochrome bc 1 :aa 3 oxidase inhibitor that also inhibits ATP synthesis. Based on its demonstrated efficacy as a monotherapy in mice and in a phase 2a clinical trial, we tested the contribution of T to novel combination therapies against two strains of M. tuberculosis (H37Rv and HN878) in an established BALB/c mouse model of tuberculosis in an effort to find more effective regimens. Overall, T was more effective in regimens against the HN878 strain than against the H37Rv strain, a finding supported by the greater vulnerability of the former strain to T and to genetic depletion of QcrB. Against both strains, combinations of a DARQ, clofazimine, and T were highly bactericidal. However, only against HN878 did T contribute synergistically, whereas an antagonistic effect was observed against H37Rv. These results demonstrate the therapeutic potential of T and highlight how differences in the susceptibility of M. tuberculosis strains could lead to different conclusions about a drug’s potential contribution to novel drug regimens. CLINICAL TRIALS This study is registered with Clinicaltrials.gov as NCT04890535 and NCT06058299 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsMycobacterium tuberculosisMice, Inbred BALB CDiarylquinolinesDisease Models, AnimalAnimalsMiceFemaleDrug Therapy, CombinationTuberculosis, Multidrug-ResistantClofazimineMicrobial Sensitivity TestsThiophenesImidazolesPiperidinesPyridines

Stichwörter der Autor:innen

H37RvHN878Q203clofaziminediarylquinolinemousetelacebectuberculosis

Substanzen

Antitubercular AgentsDiarylquinolinestelacebecbedaquilineClofazimineThiophenesImidazolesPiperidinesPyridines

Autor:innen und Institutionen

  • Center for TB Research, Johns Hopkins University, Baltimore, Maryland, USA.
  • TB Alliance, New York, New York, USA.

ORCID-Profile: Eric L Nuermberger

Zitieren

APA

Komm, O. D., Tyagi, S., Garcia, A., Almeida, D., Chang, Y., Li, S. Y., Castillo, J. R., Converse, P. J., Black, T., Fotouhi, N., & Nuermberger, E. L. (2025). Contribution of telacebec to novel drug regimens in a murine tuberculosis model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00962-24

Vancouver

Komm OD, Tyagi S, Garcia A, Almeida D, Chang Y, Li SY, et al. Contribution of telacebec to novel drug regimens in a murine tuberculosis model. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00962-24

BibTeX
@article{Komm2025,
  author = {Komm, Oliver D and Tyagi, Sandeep and Garcia, Andrew and Almeida, Deepak and Chang, Yong and Li, Si-Yang and Castillo, Jennie Ruelas and Converse, Paul J and Black, Todd and Fotouhi, Nader and Nuermberger, Eric L},
  title = {Contribution of telacebec to novel drug regimens in a murine tuberculosis model},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00962-24}
}
Kostenlos starten →